AusBiz Conference Presentation

Brad O’Connor, CEO of Cogstate, presented at the AusBiz conference earlier this week, targeting a predominantly retail investor audience to broaden market awareness. He outlined Cogstate’s strong growth outlook, driven by rising demand for digital cognitive testing and endpoint data quality services in Alzheimer’s disease, psychiatry, and clinical trials in a broad array of Central Nervous System (CNS) diseases. This demand is being fuelled by ageing populations, the emergence of disease-modifying Alzheimer’s treatments and a focus on quality of life, not just extension of life, prompting pharmaceutical companies to increase R&D investment and adopt scalable tools for assessing brain function.